Choosing the best length of oxaliplatin after stomach surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed stomach or stomach–esophagus junction adenocarcinoma and had curative surgery (D1 beta or D2 resection)
- Your cancer is stage II or III (per the AJCC 8th edition staging system)
- You are age 19 or older and can do daily activities fairly well (ECOG 0 to 2)
- You have enough bone marrow, kidney, and liver function based on blood tests
- You can understand and sign the informed consent form
- You have no spread to other organs (no metastasis), and you are not currently recovering from serious post-surgery complications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares taking capecitabine pills after curative surgery versus no further treatment. It aims to lower the chance of stomach cancer coming back in people with stage IB disease that has extra risk factors.
This trial studies whether giving oxaliplatin plus S-1 (SOX) chemotherapy before stomach surgery works best when given for different cycle lengths. It may help shrink stage III gastric cancer before a standard D2 gastrectomy and improve outcomes.
This trial compares two lengths of an oral chemotherapy medicine (9 months vs 1 year) after surgery for stage II stomach cancer. It aims to see which schedule works better and is easier to complete, while checking safety for people without major health problems.
This trial tests a combination of four chemotherapy drugs (irinotecan liposome, 5-FU + leucovorin, oxaliplatin, and Karelizumab) given before surgery to shrink stomach cancer. The goal is to see if this combination makes the cancer easier to remove and improves outcomes.
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.